Respiratory
Status Asthmaticus
13
Pipeline Programs↗
0
Active Trials↗
13
Companies Involved↗
Status Asthmaticus is an emerging landscape with 13 programs across 13 companies. The most active players are Mylan Pharmaceuticals Inc, Novartis, Boehringer Ingelheim. 8 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Analysis
Trial Status
12
clinical trials
Completed7 · 58%
Unknown status3 · 25%
Withdrawn1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
12 trials
Continuous Levalbuterol for Treatment of Status Asthmaticus in Children
Completed·—·Phase 4·NCT00124176·81 enrolled
Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
Completed·—·Phase 4·NCT00124995·40 enrolled
Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus
Completed·—·N/A·NCT04874610·15 enrolled
The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
Withdrawn·—·Phase 3·NCT03338205
Evaluation Montelukast in the Treatment of Status Asthmaticus
Unknown status·—·N/A·NCT01770899·100 enrolled
Montelukast With Status Asthmaticus, Ages 6-18
Unknown status·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2/3·NCT00494572·52 enrolled
Montelukast With Status Asthmaticus, Ages 2-5
Unknown status·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2/3·NCT00491790·52 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)